Header

In the News

14 Feb 2011 | Reuters

Lionel Melka on the Sanofi - Genzyme deal

DEALTALK-Who will blink in Genzyme, Sanofi price talks?

"We think that Sanofi was granted access to the books with a $73-$74 or maybe $73-$75 (per share) range, said Lionel Melka, co-manager of Bernheim, Dreyfus & Co's Diva Synergy Fund, an investor in Genzyme. "Sanofi is probably arguing that it discovered that manufacturing/contamination issues were worse than it thought and is trying to pay $73."

14 Feb 2011 | Reuters France

Lionel Melka comments on the Sanofi-Genzyme deal

Sanofi / Genzyme : nouvelle extension de l'OPA vraisemblable

Lionel Melka, gérant du fonds Diva Synergy, de la société de gestion Bernheim, Dreyfus & Co, estime que l'opération sera annoncée, soit mardi soir avant la fin de l'offre, soit mercredi soir une fois publiés les résultats de Genzyme, ou peu après.

08 Feb 2011 | Bloomberg

Lionel Melka comments on the Airgas-Air Products deal

Judge to rule on Airgas 'poison pill'

If the judge upholds the poison pill, it would severely damage Air Products' takeover effort. Airgas shares trading below the $70 offer reflect investor expectations that Airgas will win the case, prompting Air Products to abandon its takeover bid, Lionel Melka, an arbitrage investor in Paris at Bernheim, Dreyfus & Co. who manages assets including Airgas shares, said in an telephone interview.

08 Feb 2011 | Bloomberg

Lionel Melka comments on the Airgas-Air Products deal

Airgas Improperly Using Takeover Defense

Airgas shares trading below the offer reflect investor expectations that Airgas will win the case, prompting Air Products to abandon its takeover bid, Lionel Melka, an arbitrage investor in Paris at Bernheim, Dreyfus & Co. who manages assets including Airgas shares, said in an telephone interview yesterday.

10 11 12 13 14 15 16 17 18 19 |  20 |  21 22 23 24 25 26 27 28 29 30 31 32 33 34